Form D · Biotechnology
Denali Therapeutics Inc.
South San Francisco, CA · CIK 0001714899
Offering snapshot reported Mar 1, 2024 · SEC filing
- Reported sold
- $500M Offering amount: $500M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2024 | Initial | $499,732,711 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-506551
Source: Form D, filed Mar 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jennifer Cook | Director |
| Jay T. Flatley | Director |
| Erik Harris | Director |
| Carole Ho | Executive |
| Peter S. Klein | Director |
| Steve E. Krognes | Director |
| Vicki L. Sato | Director |
| David P. Schenkein | Director |
| Alexander O. Schuth | Executive |
| Marc Tessier Lavigne | Director |
| Nancy A. Thornberry | Director |
| Ryan Watts | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
161 Oyster Point Blvd.
South San Francisco, CA, 94080
South San Francisco, CA, 94080